ArticleTransboundary and emerging diseases2025
DDX3X Promotes Rotavirus Infection and Serves as an Antiviral Target.
Article in Transboundary and emerging diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rotavirus (RV) is a significant zoonotic pathogen primarily causing severe diarrheal disease in humans and animals, posing substantial risks to global public health and livestock industries. VP4 is one of the outer capsid proteins of RV and plays a crucial role in RV attachment and internalization. Additionally, it is also involved in replication and immune responses during RV infection; however, related studies are still limited. Here, a comprehensive analysis of the RV VP4 interactome was conducted, and DDX3X, one of six DExD/H helicase family members identified as interacting with VP4, potentially plays a crucial role in RV infection. Silencing DDX3X inhibits RV infection, whereas its overexpression facilitates RV infection. Further research demonstrated that VP4 interacts with DDX3X and the enzymatic activity of DDX3X was found to contribute to promote RV replication. Additionally, a drug screening study based on the VP4 interactome identified RK-33, a potent inhibitor of DDX3X, as the most effective candidate compound for inhibiting RV. In conclusion, VP4 interacts with DDX3X and the enzymatic activity of DDX3X is crucial for RV replication. The DDX3X inhibitor RK-33 exhibits significant inhibitory effects on RV infection. This study highlights the important roles of DDX3X in RV infection, offering potential candidate drugs for RV and expanding our understanding of its mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.